Latest news with #EQUAL
Time Business News
3 days ago
- Health
- Time Business News
Breakthrough Innovations Transforming Lung Cancer Diagnosis and Treatment
Lung cancer is a type of cancer that begins in the lungs, often caused by smoking, exposure to pollutants, genetic factors or commercial threats. Lung cancer market is increasing due to growing global lung cancer rate, awareness and increase in screening programs, progress in clinical technologies (such as low -dosage CT scans and liquid biopsy) and increasing remedies and development of targeted remedies and immunotherapy. Additionally, better healthcare in aging population and emerging areas is promoting infrastructure and early detection and demand for effective treatment solutions. Key Growth Drivers and Opportunities Growing Global Lung Cancer Rate: Rising global lung cancer rate is a major driver of lung cancer market development, as it increases the demand for early identity, accurate diagnosis and effective treatment solutions. One of the major causes of cancer-related deaths worldwide with lung cancer, healthcare systems are making heavy investments in advanced screening tools such as low-dosage CT scans and biomarker-based diagnosis to enable the first diagnosis. At the same time, rising patient numbers are accelerating the development and adoption of innovative remedies including targeted drugs and immunotherapy. The burden of growing disease also attracts more research funds and industry investment, further fuel to market expansion. Challenges The lung cancer market faces several borders, including advanced diagnosis and high cost of targeted treatments, which can limit access to areas with especially low and moderate income. Delayed diagnosis also disrupts the results of treatment due to lack of awareness, limited screening programs and non-specific initial symptoms. Additionally, the challenge of complex regulatory routes, delayed stage patients, and the challenge of managing side effects from therapy disrupts the market growth despite technological progress. Innovation and Expansion EQUAL Study Launches High-Risk Group Lung Cancer Screening Trial In May 2025, Researchers at the Dana-Farber Cancer Institute have begun testing a new, in-house blood test in an effort to screen for lung cancer and identify those who are at a higher risk of developing the disease even if they have never used tobacco. Epidermal growth factor receptor (EGFR) gene mutations can be common in the Asian and Hispanic/Latinx populations, which is the subject of the EQUAL (EGFR ctDNA Quantitative Assessment for Lung Cancer screening in Asian and Latinx populations) study. Possessing this mutation increases the risk of lung cancer because EGFR type mutations are linked to the illness. Additionally, the number of cancer diagnoses among Asian or Hispanic/Latinx individuals is increasing at a faster rate. With India's First LungLife Screening Program to Fight Lung Cancer, Apollo Cancer Centre Sets the Standard In March 2025, India's first LungLife Screening Program for early lung cancer diagnosis has been introduced by Apollo Cancer Centres (ACCs), a pioneer in state-of-the-art cancer care. Lung cancer, which makes up 5.9% of all malignancies and 8.1% of cancer-related deaths in India, is the target of this ground-breaking project. Early identification increases the survival rate and improves treatment results (LINK). Low-dose computed tomography (LDCT) early screening can greatly increase survival chances and help with early diagnosis. However, almost 80% of high-risk patients have never spoken to their doctors about screening. To allow early detection and save lives, it is imperative to improve knowledge and communication regarding lung cancer screening, particularly among high-risk individuals. Inventive Sparks, Expanding Markets The key players operating the lung cancer market include AstraZeneca, Hoffman La Roche, Eli Lilly and Company, Pfizer Inc., Merck & Co., Amgen Inc., Novartis AG, Johnson & Johnson, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb Company. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Time Business News
5 days ago
- Health
- Time Business News
Cutting-Edge Technologies in Lung Cancer Testing
A lung cancer diagnostic test is a medical procedure that is used to detect the presence of cancer cells in the lungs. These tests include imaging techniques (such as X-ray and CT scan), tissue biopsy, spit cytology, and advanced methods such as liquid biopsy and molecular tests to identify the type and phase of cancer. The growth of lung cancer diagnostic test market is inspired by increasing demand for personalized treatment based on the government's initiative for cancer screening and genetic profiling. Key Growth Drivers and Opportunities Rising Demand for Personalized Treatment: Increasing demand for personal treatment is significantly increasing the development of lung cancer diagnostic test market, as it requires accurate and wide diagnostic equipment to identify specific genetic mutations, biomarkers and cancer sub-types. Personal remedies, such as targeted drugs and immunotherapy, have greatly rely on accurate clinical consequences for tailor treatment schemes for individual patients. This has increased adopting advanced clinical techniques such as liquid biopsy, next generation sequencing (NGS), and molecular testing. Since healthcare provider and patients want more effective, less aggressive and sewn treatment approaches, the demand for high-collective clinical trials continues to promote market expansion. Challenges Lung cancer diagnostic test market faces many borders that can obstruct its growth and access. High costs associated with advanced clinical technologies such as PET scans, liquid biopsy and next generation sequencing make them less cheap in countries with less and moderate income. Additionally, delayed diagnosis in delayed diagnosis due to limited infrastructure, lack of efficient health professionals, and lack of awareness in the reduction of available tests. In some clinical methods, false positive or negative can also cause incorrect diagnosis, affecting the consequences of treatment. Regulatory barriers and variability in testing accuracy further limited widely adopting innovative clinical equipment in clinical settings. Innovation and Expansion An Innovative Lung Cancer Screening Trial for High-Risk Individuals has been launched by the EQUAL Study In May 2025, Researchers at the Dana-Farber Cancer Institute have begun testing a new, in-house blood test in an effort to screen for lung cancer and identify those who are at a higher risk of developing the disease even if they have never used tobacco. As lung cancer is becoming more common in younger people and among Asian or Hispanic/Latinx people who have never used tobacco, the team, led by the principal investigator and thoracic oncologist, associate director of Dana-Farber's Cancer Care Equity Program, designed the study. Epidermal growth factor receptor (EGFR) gene mutations can be common in the Asian and Hispanic/Latinx populations, which is the subject of the EQUAL (EGFR ctDNA Quantitative Assessment for Lung Cancer screening in Asian and Latinx populations) study. Possessing this mutation increases the risk of lung cancer because EGFR type mutations are linked to the illness. Additionally, the number of cancer diagnoses among Asian or Hispanic/Latinx individuals is increasing at a faster rate. The LuNGS Alliance has launched a Free NGS Biomarker Screening Program for Lung Cancer In March 2025, For patients with lung cancer throughout India, the Cancer Research and Statistics Foundation (CRSF)-led LuNGS Alliance has announced free lung NGS biomarker testing. AstraZeneca, Pfizer, and Roche support this program, and 4baseCare is the official lab partner. The initiative's goal is to raise awareness of precision oncology as a crucial, easily accessible, and reasonably priced therapy option for lung cancer. 4baseCare's TARGT First Solid test provides a thorough examination of 72 frequently mutated genes, revealing actionable biomarkers that allow for individualized treatment regimens based on each patient's own genetic profile. The test finds mutations that match FDA and NCCN-approved medications, enabling oncologists to offer more individualized, potent treatments that can greatly enhance patient outcomes. Inventive Sparks, Expanding Markets The key players operating in the lung cancer diagnostic test market includes Abbott, Illumina, Inc., Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated, NeoGenomics, NanoString, Myriad Genetics Inc., F. Hoffmann-La Roche Ltd, Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and Janssen Pharmaceuticals, Inc. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Bangkok Post
16-07-2025
- Entertainment
- Bangkok Post
Milli featured on New York Times Square billboard
Thai hip-hop star Milli this week appeared on a billboard in New York's Times Square - a feature by Spotify to mark the launch of her new album HEAVYWEIGHT. This is the 22-year-old rapper's second full-length album, consisting of 13 tracks, each packed with "heavy" emotional and musical intensity. The album aims to deliver powerful messages through its lyrics, mood and signature rap style that defines Milli's artistry. This is not her first time on the Times Square billboard. She was previously featured in Spotify's EQUAL campaign back in 2021. Milli, whose real name is Danupha Kanateerakul, is best known for being the first Thai artist to perform at the world-famous Coachella Valley Music and Arts Festival in the United States in 2022. During her six-minute performance, she wowed the crowd with her fast rapping and concluded the show by eating mango sticky rice onstage. Milli, recognised for her bold and expressive music, has become a vocal advocate for social issues, using her platform to speak out on matters such as gender equality and freedom of expression. Milli debuts an unreleased track from her latest album 'Heavyweight', ' Sick With It '.
CNA
16-07-2025
- Entertainment
- CNA
CNA938 Rewind - Eat, Drink, Singapore - What the puff?
CNA938 Rewind - EQUAL's Open Stables Day – meet therapy horses and have fun! In 'Destination Anywhere', Melanie Oliveiro finds out where Singaporeans and Singapore residents can go to come face-to-muzzle with therapy horses, including miniature horses and rehomed ex-racing, polo, and riding school horses. That's happening at Open Stables Day organised by EQUAL, a registered charity aiming to transform lives through animal-assisted services. EQUAL's CEO Elaine Chen will talk more about the one-day family-friendly event – taking place on 26 July 2025 - that includes guided stable tours, meet-and-greet sessions and in-depth Behind-the-Stable experiences.
CNA
16-07-2025
- Entertainment
- CNA
CNA938 Rewind - EQUAL's Open Stables Day – meet therapy horses and have fun!
In 'Destination Anywhere', Melanie Oliveiro finds out where Singaporeans and Singapore residents can go to come face-to-muzzle with therapy horses, including miniature horses and rehomed ex-racing, polo, and riding school horses. That's happening at Open Stables Day organised by EQUAL, a registered charity aiming to transform lives through animal-assisted services. EQUAL's CEO Elaine Chen will talk more about the one-day family-friendly event – taking place on 26 July 2025 - that includes guided stable tours, meet-and-greet sessions and in-depth Behind-the-Stable experiences.
